Real-World Evidence Consulting > Real-World Evidence Document your treatment impact The launch of your new medical product doesn’t mark an end to your work – it’s just the beginning. It’s important to document the impact of your medical treatment in the post-marketing phase with real-world evidence. This data is available and often requested by patients, health care practitioners (HCP) and payers. What is ‘real-world evidence’? Just like documentation in the research and development process is crucial in the receipt of medical products, the real-world data from practical use of the product is important to determine the future use of this and similar products in the market. Real-world evidence (RWE) is a term for gathering this practical data from the real world (RWD). Meet the real people behind your real-world evidence RWE projects require specialist knowledge and cross-functional collaboration. Our process transforms Nordic healthcare data into clear evidence that regulators and stakeholders understand, helping you build stronger cases for your products without the complexity. Why invest in RWE RWE’s use in the drug lifecycle Where does RWE add value in drug development? Quite simply: almost everywhere. This overview highlights how real-world data is used from early trials to regulatory approval and well after commercialization. read more Why is ‘real-world evidence’ important? Real-world evidence is becoming increasingly important to companies in the pharmaceutical industry. Real-world evidence integrates data from multiple sources across multiple study cases. This real-world data is very important to stakeholders, HCP’s and patients in order to believe in and trust the product. By analyzing real-world evidence effectively, you can react to real-world data much more rapidly which makes your level of control over the market higher. Signum consultants can help you use relevant data and appropriate methodologies to see the impact and plan your next step. Working with real-world evidence is a challenge. Organizations must work as a team and overcome the traditional barrier between medical and market access. But exploring treatment impact can also be an opportunity to sharpen your focus and target new audiences who can benefit from your product. It will also help you meet the expectations of public authorities. Real-world evidence workshop Your journey towards real-world excellence Working with real-world evidence tends to bring people together. It brings you closer to your market and an understanding of the impact your treatment has in real-life situations. read more Charting the future for Nordic pharma Forward Thinkers Review 2.0 Want to know what it takes to grow in the Nordic pharma industry over the next 3-5 years? Get the insights “We analyze the dynamics behind the market, which leads to insights based on the patient treatment reality – insights that are valuable not only to you, but to patients, HCPs and payers.” Mads Obi Bergsten Product and Portfolio Manager For more information, please contact Anne Cathrine Falch-Jørgensen Head of Nordic Real-World Evidence acfj@signumlifescience.com +45 61 776 975 Frequently asked questions Click on the arrow to expand Why is real-world evidence essential for building trust with healthcare professionals and patients? HCPs and patients increasingly expect proof of treatment effectiveness beyond clinical trials. RWE integrates data from real usage patterns, diverse patient populations, and multiple sources, offering a transparent and realistic picture that strengthens confidence in the product and the company behind it. How can RWE help pharmaceutical companies meet the expectations of public authorities and payers? Authorities and payers increasingly require evidence of real-world effectiveness, safety, and resource impact. RWE provides this data in formats regulators trust, strengthening submissions, satisfying transparency requirements, and supporting reimbursement decisions. How can real-world evidence reduce uncertainty in strategic decision-making? RWE provides a factual, data-driven view of how treatments behave under real-life conditions. This reduces guesswork, supports more precise forecasting, and helps teams plan next steps with greater confidence, whether it involves adjusting positioning, preparing submissions, or targeting new audiences. Why is Nordic healthcare data uniquely valuable for real-world evidence projects? The Nordic region offers rich, granular healthcare data. This provides a rare opportunity to follow patient journeys over long periods and analyze treatment effectiveness with exceptional accuracy. The result is more robust, credible evidence for regulators and stakeholders. In which stages of the drug lifecycle can RWE add value? RWE informs nearly every phase: from understanding patient populations in early trials to supporting regulatory approval, post-marketing surveillance, safety monitoring, and ongoing commercial optimization. It provides a continuous evidence stream that strengthens decisions long after launch. Clear examples of what we can help you with Case RWE study reveals sustained efficacy of diabetes treatment This peer-reviewed RWE study on the efficacy of diabetes treatment reveals sustained blood sugar reductions and actionable insights for improving adherence. Inspire me Case Improving ADHD treatment strategies with real-world data Learn how real-world data improves ADHD treatment strategies by offering insights into patient demographics, trends, and resource optimization. Inspire me Case Forecasting trends to drive vaccination uptake in Denmark Learn how real-world evidence improved vaccination uptake in Denmark, helped address disparities in the private market, and supported strategic planning. Inspire me
